These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Validation of the adjusted global antiphospholipid syndrome score in systemic lupus erythematosus patients in Argentina. Garcia L; Velloso MS; Martire MV; Savy F; Arizpe F; Garcia N; Testi A; Pena C; Costi AC; Isnardi C; Capelusnik D; Mazza S; Curi YS; Collado V; Rodriguez MF; Scarafia S; Pisoni C; de la Torre M; Seewald A; Riva ME; Garcia M Lupus; 2020 Dec; 29(14):1866-1872. PubMed ID: 33028177 [TBL] [Abstract][Full Text] [Related]
5. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study. Zuily S; Regnault V; Guillemin F; Kaminsky P; Rat AC; Lecompte T; Wahl D Thromb Res; 2013 Jul; 132(1):e1-7. PubMed ID: 23676348 [TBL] [Abstract][Full Text] [Related]
6. Global Antiphospholipid Syndrome Score (GAPSS) in Patients with Systemic Lupus Erythematosus. Cheldieva FA; Reshetnyak TM; Shumilova AA; Nurbaeva KS; Cherkasova MV; Lila AM; Nasonov EL Dokl Biochem Biophys; 2023 Aug; 511(1):227-234. PubMed ID: 37833610 [TBL] [Abstract][Full Text] [Related]
7. Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study. Zuily S; de Laat B; Mohamed S; Kelchtermans H; Shums Z; Albesa R; Norman GL; Lamboux-Matthieu C; Rat AC; Ninet J; Magy-Bertrand N; Pasquali JL; Lambert M; Lorcerie B; Kaminsky P; Guillemin F; Regnault V; Wahl D; Rheumatology (Oxford); 2015 Nov; 54(11):2071-5. PubMed ID: 26163690 [TBL] [Abstract][Full Text] [Related]
8. The global anti-phospholipid syndrome score in primary APS. Sciascia S; Sanna G; Murru V; Roccatello D; Khamashta MA; Bertolaccini ML Rheumatology (Oxford); 2015 Jan; 54(1):134-8. PubMed ID: 25122726 [TBL] [Abstract][Full Text] [Related]
9. Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus. Martínez-Berriotxoa A; Ruiz-Irastorza G; Egurbide MV; Rueda M; Aguirre C Lupus; 2004; 13(12):927-33. PubMed ID: 15645748 [TBL] [Abstract][Full Text] [Related]
10. Elevated partial antiphospholipid score is a strong risk factor for thrombosis in patients with systemic lupus erythematosus: a validation study. Chen J; Sun S; Yan Q; Bao C; Fu Q Clin Rheumatol; 2016 Feb; 35(2):333-40. PubMed ID: 26753544 [TBL] [Abstract][Full Text] [Related]
11. Independent validation of the adjusted GAPSS: Role of thrombotic risk assessment in the real-life setting. Fernandez Mosteirin N; Saez Comet L; Salvador Osuna C; Calvo Villas JM; Velilla Marco J Lupus; 2017 Oct; 26(12):1328-1332. PubMed ID: 28387637 [TBL] [Abstract][Full Text] [Related]
12. Influence of antiphospholipid antibody levels and type on thrombotic manifestations: results from the Serbian National Cohort Study. Stojanovich L; Markovic O; Marisavljevic D; Elezovic I; Ilijevski N; Stanisavljevic N Lupus; 2012 Mar; 21(3):338-45. PubMed ID: 21993381 [TBL] [Abstract][Full Text] [Related]
13. Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus. Martinez-Berriotxoa A; Ruiz-Irastorza G; Egurbide MV; Garmendia M; Gabriel Erdozain J; Villar I; Aguirre C Lupus; 2007; 16(10):810-6. PubMed ID: 17895304 [TBL] [Abstract][Full Text] [Related]
14. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Tektonidou MG; Laskari K; Panagiotakos DB; Moutsopoulos HM Arthritis Rheum; 2009 Jan; 61(1):29-36. PubMed ID: 19116963 [TBL] [Abstract][Full Text] [Related]
15. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Horbach DA; van Oort E; Donders RC; Derksen RH; de Groot PG Thromb Haemost; 1996 Dec; 76(6):916-24. PubMed ID: 8972011 [TBL] [Abstract][Full Text] [Related]
16. Global antiphospholipid syndrome score and anti-ß2-glycoprotein I domain I for thrombotic risk stratification in antiphospholipid syndrome: A four-year prospective study. Nascimento IS; Radin M; Gândara APR; Sciascia S; de Andrade DCO Lupus; 2020 Jun; 29(7):676-685. PubMed ID: 32279584 [TBL] [Abstract][Full Text] [Related]
18. The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematosus: a cross-sectional study. Berube C; Mitchell L; Silverman E; David M; Saint Cyr C; Laxer R; Adams M; Vegh P; Andrew M Pediatr Res; 1998 Sep; 44(3):351-6. PubMed ID: 9727712 [TBL] [Abstract][Full Text] [Related]
19. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. Somers E; Magder LS; Petri M J Rheumatol; 2002 Dec; 29(12):2531-6. PubMed ID: 12465147 [TBL] [Abstract][Full Text] [Related]